Elevate your Scientific Output with syndena insights

2024

In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation

Andrea Brunner, Gudrun Carolina Thalhammer-Thurner, Wolfgang Willenbacher, Margot Haun, Bettina Gudrun Zelger, Ella Willenbacher. PMID: 37951851

2023

Adherence to Patient-Reported Symptom Monitoring and Subsequent Clinical Interventions for Patients With Multiple Myeloma in Outpatient Care: Longitudinal Observational Study

Jens Lehmann, Kelly M de Ligt, Stefanie Tipelius, Johannes M Giesinger, Monika Sztankay, Sandra Voigt, Lonneke V van de Poll-Franse, Gerhard Rumpold, Roman Weger, Ella Willenbacher, Wolfgang Willenbacher, Bernhard Holzner. PMID: 37606979

Attrition Rates in Multiple Myeloma Treatment under Real World Conditions-An Analysis from the Austrian Myeloma Registry (AMR)

Magdalena A Benda, Hanno Ulmer, Roman Weger, Patrick Reimann, Theresia Lang, Petra Pichler, Thomas Winder, Bernd Hartmann, Irene Strassl, Maria Theresa Krauth, Hermine Agis, Siegfried Sormann, Klaus Podar, Wolfgang Willenbacher, Ella Willenbacher. PMID: 36765918

Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma

Maurus Locher, Emina Jukic, Verena Vogi, Markus A Keller, Teresa Kröll, Simon Schwendinger, Klaus Oberhuber, Irmgard Verdorfer, Beatrix E Mühlegger, Martina Witsch-Baumgartner, David Nachbaur, Wolfgang Willenbacher, Eberhard Gunsilius, Dominik Wolf, Johannes Zschocke, Normann Steiner. PMID: 36433728

2021

Clinical Outcome Assessment in Cancer Rehabilitation and the Central Role of Patient-Reported Outcomes

Jens Lehmann, Maria Rothmund, David Riedl, Gerhard Rumpold, Vincent Grote, Michael J Fischer, Bernhard Holzner. PMID: 35008247

Functional health and symptoms in Spain before and during the COVID-19 pandemic

Jens Lehmann, Bernhard Holzner, Johannes M Giesinger, Andrew Bottomley, Shaad Ansari, Ludwig von Butler, Georg Kemmler. PMID: 33933042

Implementation of daily patient-reported outcome measurements to support children with cancer

Andreas Meryk, Gabriele Kropshofer, Benjamin Hetzer, David Riedl, Jens Lehmann, Gerhard Rumpold, Alexandra Haid, Bernhard Holzner, Roman Crazzolara. PMID: 34383360

Bridging the gap in outpatient care: Can a daily patient-reported outcome measure help?

Andreas Meryk, Gabriele Kropshofer, Benjamin Hetzer, David Riedl, Jens Lehmann, Gerhard Rumpold, Alexandra Haid, Bernhard Holzner, Roman Crazzolara. PMID: 34245127

Estimating seroprevalence of SARS-CoV-2 antibodies using three self-reported symptoms: development of a prediction model based on data from Ischgl, Austria

Jens Lehmann, Johannes M Giesinger, Gerhard Rumpold, Wegene Borena, Ludwig Knabl, Barbara Falkensammer, Cornelia Ower, Magdalena Sacher, Dorothee von Laer, Barbara Sperner-Unterweger, Bernhard Holzner. PMID: 33597049

The cancer patient’s perspective of COVID-19-induced distress-A cross-sectional study and a longitudinal comparison of HRQOL assessed before and during the pandemic

Karin A Koinig, Christoph Arnold, Jens Lehmann, Johannes Giesinger, Stefan Köck, Wolfgang Willenbacher, Roman Weger, Bernhard Holzner, Ute Ganswindt, Dominik Wolf, Reinhard Stauder. PMID: 33973411

The Attitude towards Polypills Questionnaire (APPQ): a phase I-III development and validation study in patients with cerebrovascular disease

Jens Lehmann, David Riedl, Monika Sztankay, Christian Boehme, Julian Fischnaller, Stefan Kiechl, Bernhard Holzner, Michael Knoflach, Gerhard Rumpold. PMID: 34463018

Using the Computer-based Health Evaluation System (CHES) to Support Self-management of Symptoms and Functional Health: Evaluation of Hematological Patient Use of a Web-Based Patient Portal

Jens Lehmann, Petra Buhl, Johannes M Giesinger, Lisa M Wintner, Monika Sztankay, Lucia Neppl, Wolfgang Willenbacher, Roman Weger, Walpurga Weyrer, Gerhard Rumpold, Bernhard Holzner. PMID: 34100765

The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond

Irene Strassl, Martin Schreder, Normann Steiner, Jakob Rudzki, Hermine Agis, Tina Künz, Nino Müser, Wolfgang Willenbacher, Andreas Petzer, Peter Neumeister, Maria Theresa Krauth. PMID: 34572927

2020

Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.

Willenbacher E, Willenbacher W, Weger R, Dominik W, Manzl C, Brunner A. Ann Hematol. 2020 Jul 1. doi: 10.1007/s00277-020-04124-0. Online ahead of print. PMID: 32613279

The cancer patient’s perspective of COVID-19-induced distress-A cross-sectional study and a longitudinal comparison of HRQOL assessed before and during the pandemic

Karin A Koinig, Christoph Arnold, Jens Lehmann, Johannes Giesinger, Stefan Köck, Wolfgang Willenbacher, Roman Weger, Bernhard Holzner, Ute Ganswindt, Dominik Wolf, Reinhard Stauder. PMID: 33973411

The Attitude towards Polypills Questionnaire (APPQ): a phase I-III development and validation study in patients with cerebrovascular disease

Jens Lehmann, David Riedl, Monika Sztankay, Christian Boehme, Julian Fischnaller, Stefan Kiechl, Bernhard Holzner, Michael Knoflach, Gerhard Rumpold. PMID: 34463018

Using the Computer-based Health Evaluation System (CHES) to Support Self-management of Symptoms and Functional Health: Evaluation of Hematological Patient Use of a Web-Based Patient Portal

Jens Lehmann, Petra Buhl, Johannes M Giesinger, Lisa M Wintner, Monika Sztankay, Lucia Neppl, Wolfgang Willenbacher, Roman Weger, Walpurga Weyrer, Gerhard Rumpold, Bernhard Holzner. PMID: 34100765

The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond

Irene Strassl, Martin Schreder, Normann Steiner, Jakob Rudzki, Hermine Agis, Tina Künz, Nino Müser, Wolfgang Willenbacher, Andreas Petzer, Peter Neumeister, Maria Theresa Krauth. PMID: 34572927

2019

Complementing clinical cancer registry data with patient reported outcomes: A feasibility study on routine electronic patient-reported outcome assessment for the Austrian Myelome Registry.

Sztankay M, Neppl L, Wintner LM, Loth FL, Willenbacher W, Weger R, Weyrer W, Steurer M, Rumpold G, Holzner B. Eur J Cancer Care (Engl). 2019 Nov;28(6):e13154. doi: 10.1111/ecc.13154. Epub 2019 Aug 29. PMID: 31465136

Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia.

Willenbacher E, Jöhrer K, Willenbacher W, Flögel B, Greil R, Kircher B. Ann Hematol. 2019 Nov;98(11):2569-2578. doi: 10.1007/s00277-019-03797-6. Epub 2019 Oct 18.

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma.

Ludwig H, Poenisch W, Knop S, Egle A, Schreder M, Lechner D, Hajek R, Gunsilius E, Krenosz KJ, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Melchardt T, Greil R, Zojer N. Br J Cancer. 2019 Oct;121(9):751-757. doi: 10.1038/s41416-019-0581-8. Epub 2019 Sep 27.

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy.

Terpos E, Jamotte A, Christodoulopoulou A, Campioni M, Bhowmik D, Kennedy L, Willenbacher W. J Med Econ. 2019 Aug;22(8):766-776. doi: 10.1080/13696998.2019.1606002. Epub 2019 Apr 29. PMID: 30969797